AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences

Rhea-AI Summary

AVEO Oncology (Nasdaq: AVEO) announced its participation in two virtual investor conferences. The first is H.C. Wainwright’s 23rd Annual Global Investment Conference on September 13 at 7:00 a.m. ET. The second is the Baird 2021 Global Healthcare Conference on September 14 at 3:10 p.m. ET. A live webcast of the Baird conference will be available on AVEO's website, with a replay accessible for 30 days post-event. AVEO is focused on oncology, marketing FOTIVDA® for renal cell carcinoma and developing immuno-oncology combinations.

BOSTON--(BUSINESS WIRE)-- AVEO Oncology (Nasdaq: AVEO) today announced that members of its senior management team will participate in two upcoming virtual investor conferences:

H.C. Wainwright 23^rd Annual Global Investment Conference
Date: Monday, September 13
Time: 7:00 a.m. Eastern Time

Baird 2021 Global Healthcare Conference
Date: Tuesday, September 14
Time: 3:10 p.m. Eastern Time

A live webcast of the Baird fireside chat can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

About AVEO Pharmaceuticals, Inc.

AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA^® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has several other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the sections titled “Risk Factor Summary” and “Risk Factors” in AVEO’s quarterly and annual reports on file with the Securities and Exchange Commission (SEC) and in other filings that AVEO makes with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.

Any reference to AVEO’s website address in this press release is intended to be an inactive textual reference only and not an active hyperlink.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005039/en/

AVEO Public Relations:

David Pitts, Argot Partners

(212) 600-1902

aveo@argotpartners.com



AVEO Investor Relations:

Hans Vitzthum, LifeSci Advisors

(617) 430-7578

hans@lifesciadvisors.com

Source: AVEO Oncology

FAQ

What investor conferences is AVEO participating in September 2023?

AVEO will participate in H.C. Wainwright's 23rd Annual Global Investment Conference on September 13 and Baird's 2021 Global Healthcare Conference on September 14.

What time will AVEO's presentations occur during the conferences?

The presentations will take place at 7:00 a.m. ET on September 13 and at 3:10 p.m. ET on September 14.

How can I access the webcast for AVEO's investor presentations?

The live webcast for AVEO's presentations can be accessed on their website in the investors section.

What is AVEO's primary focus as a biopharmaceutical company?

AVEO is focused on developing and marketing treatments for oncology, particularly for renal cell carcinoma.

What product does AVEO currently market?

AVEO markets FOTIVDA® (tivozanib) for the treatment of adult patients with relapsed or refractory renal cell carcinoma.